KHAN G S. RESEARCH CENTRE COST) > owe Uw wepfe Fieres (ae) #1 oa Sat sae th raat pH aR 74 een é sein ae ent then 2 rer a SL cet a Ui, Sas FA MT FI 7% FM ZI > oafeeif ¥ yeu at orien aren cet 1 blood eat #1 em fates dee veel ven tai an oar ae 21 > waa fain ae gm (ert) oraeem F ates A eer 31 aren ae A aa ao PRO afer F cia 21 waa Teter A fare (Spleen) ¥ wT Wa * saiq Spleen *t BloodBank Eel Aa #1 wm tear at ats fafa rd 4 fara tH OF aes HI SI EE 180 J 200 gm Bat @ 8 Blood cH ‘sf (oR =m (55-60%) (40-45%) (1) reheat (2) stirs WBC Plate lets, TH aT TE A ET, AT & SHAT 90% AML Se Bat & aie 10% aM A widis aon raleredz ela @1 ee 49a or aren stata efaitsa cen seit ater 21 ae etal ata ca et RT aa (SA) Hes ae a ‘a (Serium) Wa cH eee 4 a wefeisa are ae fara ca @ ah as ae gen ca Ah aH ae z1 ARH ved Gil tr a tien @, steal at si am ai ort 2 efuaia (Corpuscle) ae aa a aires am eter Bes ae a Faiz aaa ZI 1. R.B.C, [Real Blood Corpuscle] Ta Tat =ftreat > Shar] #1 :990% FT RBC. tel #1 RBC. #t Re AEN 5 ffera (10 ara) tid @ 2 RBC a Saxe ce ae Fei eT oo 31 gs By : Khan Sir grafts fatwa)KHAN G S. RESEARCH CENTRE > vo V8v008 or eo evo” 8 RBC i uate dt wed 1 RBC ar San are 120 fea Ste 2) sea Frain afer A et 21 oT ‘aeen 4 gaan Frater aga (Liver) ¥ ea #1 aaa GH RBC Spleen Far AEA A WA TS Bt aA #1 Spleen al RBC I %a AI Grave yard ed @1 RBC #1 Wer arf sao wet CO, I afaer FEM ZI RBC 4 etirehfar wa ora & ai eaves (Hb) F et eT TT wT cet Fa 2 eriveifas F citer (ron) wer sre 21 Acie COB LS LHL HLS RM RIS Garces ation da CO, #1 after a #1 Je (Male) 4 aarcifaa a1 KK 149m vf 100 ML Fat #1 Female (afeen) 4 eriveitfat #1 =e 139m GA 100 ML eat i Remark: @avcifaa } ai S are wiiftren (saan) ae Ayal) W.B.C. [White Blood Corpuscle] 9a Ta ahfurest ‘FAFT FEA 3000 F 10000 F ats eit 1 eas aw eye! Bes Marcia aT eit SL Aare ze aeq in at frat 21 WBC 1 areR aiftatia dia @1 WBC #1 fain safer Acta 2) eam Viarara 4 fe ata 21 RBC : WBC = 600: 1 WBC #1 cqalaee 4} wed #1 WBC 4 dar (fant) & aan # sei tat Aart wen aay WBC 8 WAR Far BIT Bo 1. Eosino - phil 2. Baso - Phil Bacteria 4 Neutro - Phil Mono ~Gyte - 344 Tet Lympho - Cyte— Antibody #1 Fatt 1 Ve 1 ele 1 el Mofo Cyte amex aaa ser ate ZH Lympho - Cyte Antibody a7 fanin area & st Sak eek AY wire meet 21 ‘Lympho - Cyte i T-Cell And B - Cell 9rft Sidi #1 ante’ A yer wa A em (afer) 11 1 ISI aL els wee Plate lets ( farrarray ) 3a gata ot aed #1 ae aa a ose aa A ee ae seal ae Ga aera FH ae BI ae hen #1 ge Stara 4.5 fH tien #1 fa wnice oY gat den 2 a3 ore #1 Sy ond Yeah der 50,000 4 sft aH a ait @ Tae oT Tt 2 > wae TS shea ceed fees a #1 war ais CO, Tar 0, 3 ear FT #1 ys 4 By : Khan Sir grata fatwa)KHAN G S, RESEARCH CENTRE 2 Ta sais wel a free acm 2 2 wan @ fifa wer fat ar @ fe Fie TER Spleen wafaa eS arr we a TT fix art @1 ‘eftaet (Lymph) ae tee tl oh aT He Biot Bee Hb FET VT SIT Bh eee A aeR are cafe whe oe oA BI fT catia Frere ari vented eter 21 cafe a ware Sac ww fee Foci sag, ae sitar a ar at ait ort 21 cater wit i dea S sar @ een wie A afataa se i avira ee et Bl cafe O, FI atte CO, sfae ata #1 ae aa wa a ard eat #1 ze GTA RBC Ta Plateless H A= A UPA at ti tier tart 3 cnfaen da wenfaa et on 21 Ta BT AeRHT (SAT) SAAT (Clotting) 2 > 2 2 v 8 ade 4 fat we cer ea FIT ST eh GFT THT FI Clotting eea By aa I FaaT 2 85 fire wat S oe wat a finer BACH) Cascale process Fue Te a area freifertiad fara ae TAA FI va adi mea ¢ ot wie aaa at nt sie aa & ae A cr eae aro an soe wala (Plalilets) warenfzs ¥ aa sat BH ae rniccnien afer 4 fan ah ages 4B safeaa werd a ara a ace Sta #1 ae si ea 8 ved safer weft 3 fears wari y are fa 21 confer #1 Ta ae Fe TAB z food ca 4 Shey (Ger ey SRBC) SORT Sie 2 POT eM a aes Be OTe ea aa aT EU FHT Tt 1 galass + aq > warenfet % arene + Cas weir] = eit 3. afar sumrefaien arefst 4. wigs + BATT (RBC) > Ta #1 eT Tan Page 8 aftart vere fae ess wher, > aria (Plateles) waa > Ca wer > Hiiee war weiter Remark: @4ta (wai a vem) FH frat KB) eS eR aA GA TA Oa ah oafaa wt AL a Lae & sree oot are waa War are @ St eS or aa HI eT a da @ aa: SH Fi Anticlotting @ Anti coagulant #ea ZI aah aq S wee So ae a ont a fife a ont @ af aa a aaa aa ae Sriviiern we asi a 21 ga an Hoga a oe ae aT 2 aa: Fea Ge aera wel Sa ae ata wee ai eR Cede S we EAT DG ST By : Khan Sirgnafes fase)KHAN G S. RESEARCH CENTRE > wea a a de She ae fae 3 feo Dara 4d qe ey a an ver Soe oe oe oe ie aa BER aT eT 33 Zt TH ag & fafa + a RBC A yar VM aren vagal sie @ fad cis ee Fe a fe aT Antigen @ wan % @i @ A TH B FA Antigen S SAR HR TA HH UR AMF aienel i fat Antigen A 2 Fe Blood Group A. fai Antigen B #1 4é Blood Group B 3. fai Antigen AB @Fi BT az Blood Group AB 4. faa Antigen Fé ET Ae Blood Group O. ww cae A et oe van wi aia oer aim? fra Antibody wea 21 AB Antibody ata 4 tea Sem 31 4 Antibody 1 faaim faerie Fem ti Remark = Rh — Factor :— yaat Gia 1940 8 dace cen dhe 4 fran ae we fae Ga I Antigen Hale fas waa wed fs ame aH ta Ml ata: FA Rh Bea A faa ae Rh sofa wat # SaRh SPositive(Rh®) ed #1 fei we Rh wT wat Ta Rh- Negative ea ZI 1 Sma H 95% im cimt_Rh Positive @ ission of Blood (Tat STE ):— va feat cafe at are 4 aa Rea oe @ a sa ae eT SI ae ZI Blood Bank 1 74 40% *R Tal Wal #1 ue aif we aa we aRelsetd 200Mu AR # Fea @ ‘ane th AP Blood #1 4e4 1200 4 2000 %. A ata wear 21 Wa FA Ge 1 SI Hea Z A Blood Group * Aa-a4 Rh I ht fra He zi ‘af 4 Rh are feet Rh* ae #12 2 at cee aR A aw el om fag Gad aR Rh— aren oad i ay Sse) safe ca feafe aa orerfie face et ore @ sik aera wena tt om 21 ca Ta a after eed Z1 Remark: O-Ve ara tH I arf sen (Universal Doner) er et & Fie ee a WHR Fe Antigen 72 Rh War Sa Zh sfeatereiiea cafe fran aT Rh‘ve ait art aT Rh’ Bee fafa Yo vec Aare ae yard zat vem fer seh are at aor ya Aer eit om ae eS ge ae 7: 4 By : Khan Sir gratis fatwa)KHAN G S, RESEARCH CENTRE. > wai oa Oe a: FTF BT RT (1) OxA @Q) OxB G) OxXAB () Oxo (5) AXA (6) BxB () ABXAB (8) AXAB (9) BxAB (10) AxB > af (Blood Group):— 4 TH zai Antigen A,B, O erat @1 Group #e4 @1 Bo Jes Joong we A wea aa 2 | S14: $4 Bombay Blood